Xilio Therapeutics (XLO) Free Cash Flow (2020 - 2026)
Xilio Therapeutics (XLO) posted Free Cash Flow of -$22.9 million for Q1 2026, down 1034.74% sequentially from -$2.0 million in Q4 2025, and down 179.83% YoY from $28.7 million in Q1 2025.
Xilio Therapeutics (XLO) Free Cash Flow (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Free Cash Flow for 7 years, with the latest figure at -$22.9 million in Q1 2026.
- Quarterly Free Cash Flow fell 179.83% year-over-year to -$22.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$57.0 million (down 374.2% YoY) and the FY2025 annual result came in at -$5.4 million, up 70.48% from the prior year.
- Free Cash Flow declined to -$22.9 million in Q1 2026 per XLO's latest filing, from -$2.0 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $28.7 million in Q1 2025 and troughed at -$25.4 million in Q1 2023.
- A 5-year average of -$11.3 million and a median of -$14.6 million in 2025 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2025 and 2026: Free Cash Flow jumped 372.6% in 2025, then sank 179.83% in 2026.
- Over 5 years, Free Cash Flow stood at -$16.9 million in 2022, then rose by 20.48% to -$13.4 million in 2023, then retreated by 5.48% to -$14.2 million in 2024, then soared by 85.75% to -$2.0 million in 2025, then plunged by 1034.74% to -$22.9 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$22.9 million, -$2.0 million, and -$17.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Xilio Therapeutics | 178.33 Mn | 42.29 Mn | - | -18.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.78 Mn |
| Jun 30, 2026 | -18.78 Mn |
| Mar 31, 2026 | -22.90 Mn |
| Mar 31, 2026 | -22.90 Mn |
| Dec 31, 2025 | -2.02 Mn |
| Dec 31, 2025 | -2.02 Mn |
| Sep 30, 2025 | -17.50 Mn |
| Sep 30, 2025 | -17.50 Mn |
| Jun 30, 2025 | -14.61 Mn |
| Jun 30, 2025 | -14.61 Mn |
| Mar 31, 2025 | 28.69 Mn |
| Mar 31, 2025 | 28.69 Mn |
| Dec 31, 2024 | -14.16 Mn |
| Dec 31, 2024 | -14.16 Mn |
| Sep 30, 2024 | -13.68 Mn |
| Sep 30, 2024 | -13.68 Mn |
| Jun 30, 2024 | 19.95 Mn |
| Jun 30, 2024 | 19.95 Mn |
| Mar 31, 2024 | -10.52 Mn |
| Mar 31, 2024 | -10.52 Mn |